Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 28-Nov-2022 16:28:45. This version was issued on 28-Nov-2022 16:28:45

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Ambulance Trusts
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • Acute Trusts
  • NHS Trusts (England) - Chief Executive

Action category: Action

Title: Baricitinib for patients hospitalised due to COVID-19 (Adults and Children aged 2 years and over)

Broadcast content:
The published UK wide interim clinical commissioning policy, providing access to baricitinib (Olumiant) for patients admitted to hospital to manage the symptoms of COVID pneumonia, has been updated following consideration of the recommendations of the updated World Health Organization clinical guideline.  In admitted patients with severe or critical COVID-19 baricitinib may be used as an alternative to interleukin-6 (IL-6) inhibitors, or in combination with corticosteroids and IL-6 inhibitors, according to clinical judgement. The summary clinical guide, covering all of the routinely available COVID treatment options for patients admitted to hospital due to COVID, has been updated accordingly.   

Clinicians are encouraged to continue to proactively support recruitment into trials developing further evidence in the treatment of COVID-19. Patients admitted to hospital due to COVID may be considered for entry into the RECOVERY or REMAP-CAP trials. 

Additional information: This alert does not need to be cascaded to Primary Care.

Alert reference: CEM/CMO/2022/017


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency